Quintiles Launches Expanded Partnering Group as 'NovaQuest' and Announces Alliance With Top Global Investment Firm

Research Triangle Park, North Carolina (ots/PRNewswire) -

- Alliance with TPG-Axon reinforces capabilities of NovaQuest,
which has US$1.5 billion committed to partnerships with pharma and
biotech companies

Quintiles Transnational Corp. today announced the launch of its
expanded strategic partnering group under the NovaQuest(TM) brand
and, to further NovaQuest's mission, an alliance with TPG-Axon
Capital, a global investment firm with over US$5.8 billion in equity
capital. NovaQuest helps life-science companies realize greater value
from their product portfolios through innovative strategic partnering
solutions.

TPG-Axon, led by the former head of Goldman Sachs' Principal
Strategies Department, Dinakar Singh, will be NovaQuest's first-line
partner for significant co-development and co-promotion investments.

Since 2000, when Quintiles started a formal strategic partnering
function, more than US$1.5 billion has been invested or committed to
Quintiles' partnerships with companies of all sizes. Within NovaQuest
are Quintiles' key investment partnering functions, including
agreement structuring and due diligence (formerly known as PharmaBio
Development) and alliance management.

Through its alliance with TPG-Axon, NovaQuest has access to
capital to fund strategic partnerships of virtually any size.
TPG-Axon already has committed several hundred millions of dollars to
NovaQuest partnerships to date.

"NovaQuest's launch and its alliance with TPG-Axon is confirmation
of the power of partnering with Quintiles," said Quintiles
Transnational founder, Chairman and Chief Executive Officer Dennis
Gillings, Ph.D., CBE. "Customers can tap into our global development
and commercialization infrastructure, deal-making expertise, and
financial resources to create tailor-made solutions to their most
significant strategic and financial challenges."

Singh, founder of TPG-Axon, said: "This alliance further enhances
TPG-Axon's ability to find, analyze and act on non-traditional
investment opportunities in the life sciences. I believe NovaQuest
offers pharma and biotech companies 'smart money' - financial
solutions backed by Quintiles' expertise and capabilities in global
product development and commercialization. This is a powerful
resource for pharma and biotech companies seeking new solutions to
major challenges."

NovaQuest offers partnering solutions in three major categories:
- Co-development and co-promotion investments in which NovaQuest invests
with cash or Quintiles services, or a combination of both, in a
customer's drug development or commercialization programs. TPG-Axon
will be NovaQuest's partner for investments of this type.
- Strategic resourcing to convert fixed-cost assets to variable cost,
while giving customers continued access to these assets as needed.
This allows companies to advance a single product or an entire
portfolio more cost-effectively.
- Emerging biotech focused on helping small and medium-sized biotechs
access Quintiles as a "virtual infrastructure" for global development
and commercialization, often in combination with tailored financial
assistance.

NovaQuest has scientific, medical and market intelligence experts
who evaluate product or portfolio opportunities; finance and legal
experts with proven experience in structuring partnerships tailored
to each customer's specific needs; alliance managers who manage the
life-cycle of each partnership; and a group dedicated to serving
emerging biotech companies.

NovaQuest will be led by Ron Wooten, Executive Vice President,
Corporate Development, Quintiles Transnational, who has overseen the
development of Quintiles' partnering capabilities since joining the
company in 2000.

"In less than seven years, we've seen partnering grow from a
promising concept to a proven strategic option," Wooten said.
"NovaQuest's launch reflects the maturity of Quintiles' partnering
capabilities, our record of success and increasing demand from
customers. Doing business as usual isn't enough anymore. Customers
need alternative growth strategies designed around their specific
challenges and goals. NovaQuest is here to provide those solutions."

About NovaQuest and Quintiles Transnational

NovaQuest, the strategic partnering group of Quintiles
Transnational Corp., is dedicated to generating alternative growth
strategies for pharmaceutical and biotechnology companies, and offers
them a better business approach to derive the most value from their
product portfolios.

Quintiles Transnational is the global leader in pharmaceutical
services. We improve healthcare worldwide by providing innovative,
quality professional expertise, market intelligence and partnering
solutions to meet the dynamic needs of the pharmaceutical,
biotechnology and healthcare industries. Quintiles has 16,000
specialized employees and offices in 50 countries. For more
information visit the company's Web site at www.quintiles.com.

About TPG-Axon Capital

TPG-Axon Capital is a leading global investment firm with over
US$5.8 billion of capital invested in public and private markets
around the world. Through offices in New York City, Hong Kong and
Tokyo, TPG-Axon Capital has invested across a broad range of
industries in more than 20 different countries, including investments
in healthcare, pharmaceuticals, financial services, technology,
energy and basic materials and retail.

Web site: http://www.quintiles.com

ots Originaltext: Quintiles Transnational Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media, Pat Grebe, +1-919-998-2091, or media.info@quintiles.com, or
Investors, Greg Connors, +1-919-998-2000, or invest@quintiles.com,
both of Quintiles Transnational Corp.; FCMN Contact:
jay.johnson@quintiles.com